Last update 01 Nov 2024
SY-5007
Last update 01 Nov 2024
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms |
Target |
Mechanism RET inhibitors(Tyrosine-protein kinase receptor RET inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
10
Clinical Trials associated with SY-5007[14C]SY-5007在中国健康成年男性受试者体内的物质平衡研究
[Translation] Study on the material balance of [14C]SY-5007 in healthy adult male subjects in China
An Open-Label, Single-Center, Single-Dose, Phase I Study to Assess the Mass Balance of [14C] SY-5007 in Healthy Male Subjects in China
A Randomized, Open-label, Two-period, Self-controlled Study to Evaluate the Effect of Oral Rifampicin or Itraconazole on the Pharmacokinetics of SY-5007 Tablets in Healthy Subjects
100 Clinical Results associated with SY-5007
Login to view more data
100 Translational Medicine associated with SY-5007
Login to view more data
100 Patents (Medical) associated with SY-5007
Login to view more data
100 Deals associated with SY-5007
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| RET fusion-positive Non-Small Cell Lung Cancer | Phase 3 | CN | 20 Jun 2023 | |
| Advanced Malignant Solid Neoplasm | Phase 2 | CN | 23 Apr 2021 | |
| Thyroid Cancer, Medullary | Phase 2 | CN | 23 Apr 2021 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 2 | Advanced Malignant Solid Neoplasm | Non-Small Cell Lung Cancer | Thyroid Cancer, Medullary RET-fusion positive | 105 | (owrqsykaph) = ulruccecoy oxgrgrxtmr (xynfiaeybs, 67.9 - 84.8) View more | Positive | 24 May 2024 | ||
NCT05278364 (ASCO2023) Manual  | Phase 1 | RET fusion-positive Solid Tumors RET positive | 60 | (twnwrgvksa) = yawecwhage byhnpocwtm (kefkppeqzn, 72.7 - 97.8) View more | Positive | 31 May 2023 | |
(NSCLC+MTC) | (twnwrgvksa) = lkuhjfqpoc byhnpocwtm (kefkppeqzn, 73.0 - 99.0) View more |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free